Brokerages Set Liquidia Co. (NASDAQ:LQDA) Price Target at $24.00

Shares of Liquidia Co. (NASDAQ:LQDA) have received an average rating of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $25.38.

A number of analysts recently issued reports on the stock. Lifesci Capital began coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a report on Thursday, November 14th. Finally, Wells Fargo & Company began coverage on shares of Liquidia in a report on Friday. They set an “overweight” rating and a $20.00 price objective on the stock.

Liquidia Trading Up 4.8 %

NASDAQ:LQDA opened at $11.10 on Tuesday. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99. The firm has a market cap of $939.47 million, a price-to-earnings ratio of -6.81 and a beta of 0.22. The company’s 50-day moving average is $10.91 and its two-hundred day moving average is $11.16.

Insider Buying and Selling at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 3,892 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at $3,456,054.36. This trade represents a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the transaction, the insider now owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,007 shares of company stock valued at $245,780 over the last ninety days. Corporate insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Large investors have recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of Liquidia in the second quarter valued at $27,000. Clear Harbor Asset Management LLC purchased a new position in Liquidia in the 3rd quarter valued at about $100,000. Signaturefd LLC grew its stake in shares of Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of Liquidia during the third quarter worth about $110,000. Finally, Whitcomb & Hess Inc. lifted its stake in shares of Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after acquiring an additional 1,074 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).